To add a bio or update investment portfolio click update information.
Oshen Bio: Investment Portfolio & Startup News
Oshen Bio
Investment Portfolio
Healome Therapeutics
7 Jul 2026
Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
Healome Therapeutics is a University of Birmingham spinout developing an eye-drop matrix technology that extends the residence time of therapeutics on the ocular surface. The platform is designed for use in dry eye disease, ocular surface inflammation, corneal injury and rare diseases causing severe ocular surface damage.
Scarlet Therapeutics
11 May 2026
Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases
Scarlet Therapeutics develops engineered red blood cells designed to treat metabolic diseases and address shortages in rare blood supplies. Scarlet Therapeutics uses synthetic biology and proprietary cell line technology to create lab-grown red blood cells that can be manufactured at scale for therapeutic and transfusion use.
Oshen Bio
- 2(12 months)
- oshenbio.com
- Update Information
More venture news
- 16 Oct 2026
Unravel HealthUnravel Health raises a £2.5m seed round led by Conduit and Wrightwood for daily at-home saliva hormone readings
SeedHealth - 19 Oct 2026
CoComplyCoComply raises a £1.9m seed round led by Mercia Ventures to reveal hidden external workforce compliance risk
SeedLegal - 15 Oct 2026
MedcotecMedcotec announces its £2.4m seed round from VCs to help pharma manufacturers transfer powders with single-use valves
SeedLife Sciences
